IFOND research | LHON treatment prospects | Mitochondrial Genome Editing | COVID-19 and LHON | LHON talks | Pay it forward | Mitochondrial Regulation | Avoid BAK eye drop preservative, etc. | We experiment with cigarette smoke so you need not. | Viral vector trials | EPI-743 LHON trials | Idebenone LHON trialsDigests: NEI News | Mitochondrial Disease News LHON | ARVO Journals LHON | PubMed LHON | Europe PMC LHON | MRC-MBU news
IFOND is an extremely lean, all volunteer 501(c)(3) tax status registered nonprofit. Our process minimizes costs and maximizes funding for researchers' direct, non administrative expenses. All donations are tax deductible in the United States of America. Our recent tax returns are here or also here. Our scientific board includes many of the prominent world leading published researchers in optic neuropathies. If this big bang for your buck model appeals to you, please donate. If you are a researcher in optic neuropathy, we welcome your funding application.
IFOND projects update March 2022
Below is an extract from the March 2022 IFOND board meeting:
5. Research reports of scientific board members:
• Alfredo: Two parallel approaches to studying LHON:
• Computational chemistry of the G3460A mutation of ND1 (the most severe form of LHON):
to determine the structure of the normal and mutated ND1, and how this mutation affects the transfer of electrons from ND1 to ubiquinone. They found that the substitution of amino acids alanine to threonine at position 52 “leads to an additional -OH right in the path of the moving ubiquinol”. Consequently, it “creates electrostatic forces that ultimately block movement of ubiquinol and generates ROS” (reactive oxygen species), which are detrimental to “retinal ganglion cells, their fibers in the optic nerve and ultimately cause blindness in LHON” (quotations are from Alfredo’s working manuscript). See also Alfredo’s Progress Report
• Using cybrids from Valerio and UCLA, they found that the rate of mutation of ND1 changes with temperature. The conversion of alanine to threonine at position 52 may be associated with electrostatic attraction and electron tunneling, requiring extra energy to overcome it.
• He will be organizing an International meeting in Bologna in June of 2023 on mitochondrial diseases. He said that it may be good to have a LHON meeting attached to it. Fred indicated that IFOND may consider raising funds to support the LHON meeting. He asked if Valerio and Chiara can submit written outlines of their current research activities to the Board for consideration.
• His paper on mitophagy (which utilized electron microscopy in Los Angeles) submitted to Cell Reports is undergoing a second round of revision, which requires 6 months to do the experiments. When complete, he will share the paper with the Board.
• He is undertaking whole genome sequencing of 20 Brazilian family members: both affected individuals and unaffected carriers.
• He will be submitting a proposal to RDMM for possible co-funding by IFOND as described above.
• His AI (artificial intelligence) project is finally underway, as Ottawa is getting an OCTA (optical coherence tomography angiography). He will analyze the AI data and determine if those from Canada (his) and UK (Patrick’s) correspond with those from the US and Italy, the latter groups being obtained from trained medical personnel (i.e., not AI). This will help to determine if the model is correct.
• Benson Chen, MD, is formally accepted as a PhD student by the University of Cambridge.
• Benson has developed a patient-reported outcome measure (PROM) questionnaire for patients with inherited optic neuropathies. Stage One has been completed, resulting in a publication and another one in press. Stage Two involves Zoom Pro with about 20 participants with LHON or ADOA (autosomal dominant optic atrophy). The transcribed interviews will be analyzed with a software package (NVivo 12). The final phase will be in a year.
• Benson is also involved with a project to standardize nomenclature used for LHON. This project was spearheaded by Rustum and Lissa (Poincenot).
• Please see Patrick’s Progress Report.
6. Possible IFOND-funded meetings:
• Fred raised the possibility of IFOND funding a 1-2 day meeting in association with established national or international meetings (such as ARVO, NANOS, etc.). The Board can come up with a list of guest speakers. Alfredo mentioned that such has been done in the past in conjunction with ARVO. The 2023 meeting in Italy organized by Valerio will be a good venue, and it would be good to invite Solange from Brazil to speak.
7. Brazil 2022?
• Rustum indicated that it will not be feasible to go to Brazil in 2022 due to COVID.
The generous support of the donors to IFOND
continues to allow important progress in clinical and basic science investigations of Leber's Hereditary Optic Neuropathy
(LHON). Since 2001 we have sponsored regular annual field trips to rural Brazil in order to study the largest LHON pedigree in
the world. These investigations have been fully described in previous reports.
They have also led to numerous peer-reviewed publications and Association for Research in Vision
and Ophthalmology (ARVO) annual symposium presentations. These investigations and publications
have changed the face of LHON as studied, taught and clinically treated. This is an outstanding achievement for the researchers who punch well above their
weight on shoe string budgets and volunteer support.
Here find links to published peer reviewed papers acknowledging IFOND's help. This research helped stimulate a cascade of broad research on mitochondrial and optic nerve disease.
The International Foundation for
Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
Web site: http://www.ifond.org/
IFOND is registered service mark of
The International Foundation for Optic Nerve Disease, est. October 1995.
Copyright 1999-2022, International Foundation for Optic Nerve Disease.
The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.